ArticleCancer immunology, immunotherapy : CII2026
GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsSarcopenia, cachexia, and malnutrition are common in patients on immune checkpoint inhibitors (ICIs). GLP-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management in patients with obesity, including those with cancer. Whether GLP-1 RA use at ICI initiation relates to wasting-related outcomes in patients without diabetes is unknown. We examined whether GLP-1 RA supply at ICI start was linked to wasting-related diagnoses and acute-care use. MATERIALS AND
methodsWe used target-trial emulation with TriNetX US data. Adults with cancer and obesity/overweight starting an ICI were included. Baseline diabetes in the prior 12 months were excluded, with a 90-day GLP-1 RA washout. Exposure was a GLP-1 RA prescription or administration within a prespecified 30-day peri-initiation window before or after ICI initiation, versus none. Cohorts were 1:1 propensity score matched and followed up to 36 months; associations were estimated with intention-to-treat Cox models.
resultsAfter matching, 1974 patients were analyzed (987 per group). Over 36 months, GLP-1 RA overlap was associated with fewer immune-related adverse events (HR 0.63, 95% CI 0.50-0.79); hospitalization (HR 0.67, 0.51-0.89), ICU (HR 0.69, 0.53-0.90), and emergency department visits (HR 0.68, 0.53-0.89) were also lower.
conclusionsGLP-1 RA add-on at ICI initiation was associated with fewer recorded wasting-related diagnoses and less acute-care use. The all-cause mortality reduction is exploratory, likely reflecting channeling bias rather than causation. These findings support prospective evaluation of GLP-1 RAs as supportive-care add-on therapy in ICI-treated patients with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.